Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑term hormonal contraception and may also be used to manage heavy menstrual bleeding in women of reproductive age. GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert is a hormonal intrauterine system that acts on the reproductive tract to prevent pregnancy and treat menstrual disorders. - Contraception (prevention of pregnancy): offers up to five years of highly effective reversible birth control. - Heavy menstrual bleeding: reduces menstrual blood loss and improves cycle regularity. - Endometrial protection: suppresses endometrial proliferation, helping to manage hormone‑related uterine conditions.

Levosert may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods) after initial months. - Pelvic or uterine cramping. - Breast tenderness or enlargement. - Ovarian cyst formation. - Headache or mild nausea.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Device expulsion or displacement. - Pelvic inflammatory disease or severe infection. - Ectopic pregnancy if contraception fails. - Allergic reaction to device materials. - Severe abdominal pain requiring medical evaluation.

Before insertion and during use, certain precautions should be observed to ensure safety and effectiveness. - Pregnancy testing: confirm the patient is not pregnant prior to insertion. - Uterine abnormalities: evaluate for fibroids, congenital anomalies, or scarring that may affect placement. - Active infection: defer insertion if pelvic infection or sexually transmitted disease is present. - Bleeding disorders: assess coagulation status and advise on potential increased bleeding. - Hormone‑sensitive conditions: avoid use in known breast cancer or severe liver disease. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levosert has limited systemic exposure, but certain drugs can affect levonorgestrel levels.

Major Interactions (Avoid): - Rifampicin and other strong CYP3A4 inducers: may markedly reduce contraceptive efficacy. - St. John's wort (hypericum perforatum): can lower levonorgestrel concentrations.

Moderate Interactions (Monitor Closely): - Antiretroviral protease inhibitors (e.g., ritonavir): may alter hormone metabolism. - Certain anticonvulsants (e.g., carbamazepine, phenytoin): may modestly decrease effectiveness. - Antifungal agents (e.g., ketoconazole): could increase levonorgestrel exposure, requiring monitoring.